OverviewCoherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
|03/13/17||Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results|
|REDWOOD CITY, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the fourth quarter and full year 2016.
Corporate Highlights for the Fourth Quarter 2016 Include:
Oncology therapeutic franchise:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate)
- Announced that the U.S. FDA has accepted the filing of 351(k) Biologics License Application (BLA) for CHS-1701. The first FDA submissi... |
|03/06/17||Coherus Addresses Trade Secret Action Filed by Amgen|
|REDWOOD CITY, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Amgen has filed a trade secret action in California state court on March 3, 2017 alleging trade secret misappropriation and other claims against Coherus and other parties.
“Coherus believes that this action is without merit and will defend against it vigorously,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “We categorically reject the theme of Amg... |
|03/02/17||Statement by Coherus CEO Regarding Biosimilars User Fees|
|REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that Coherus BioSciences’ Vice President of Government Affairs, Juliana Reed testified in support of the reauthorization of the Biosimilar User Fee Program for FY2018 –FY2022 (BsUFA II) on behalf of the Biosimilars Forum at the House Energy and Commerce Committee hearing on FDA’s generic drug and biosimilar user fee programs.
Ms. Reed spoke in support of the reauthorization of B... |
|03/02/17||Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint|
|REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira in healthy subjects. The study met the criteria for clinical PK similarity on all prospectively defined PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first ... |
|There are currently no events scheduled.|
Receive E-mail Alerts
|Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.|